Bausch Health Companies Inc. Payments to Acquire Productive Assets
Bausch Health Companies Inc. (BHC) reported Payments to Acquire Productive Assets of $215.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2024-02-22
- Bausch Health Companies Inc. payments to acquire productive assets for fiscal 2023 was $215.00M, a 2.27% decline from fiscal 2022.
- Bausch Health Companies Inc. payments to acquire productive assets for fiscal 2022 was $220.00M, a 18.22% decline from fiscal 2021.
- Bausch Health Companies Inc. payments to acquire productive assets for fiscal 2021 was $269.00M, a 10.93% decline from fiscal 2020.
- Bausch Health Companies Inc. payments to acquire productive assets for fiscal 2020 was $302.00M.
| Period end | Payments to Acquire Productive Assets 12 month | Payments to Acquire Productive Assets 12 month as first filed |
|---|---|---|
| 2023-12-31 | $215.00M 10-K · filed 2024-02-22 | |
| 2022-12-31 | $220.00M 10-K · filed 2024-02-22 | |
| 2021-12-31 | $269.00M 10-K · filed 2024-02-22 | |
| 2020-12-31 | $302.00M 10-K · filed 2023-02-23 | |
| 2019-12-31 | $270.00M 8-K · filed 2022-05-11 | |
| 2018-12-31 | $157.00M 8-K · filed 2021-05-04 | |
| 2017-12-31 | $171.00M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $235.00M 10-K · filed 2019-02-20 | |
| 2015-12-31 | $235.00M 8-K · filed 2018-08-10 | $235.20M 10-K · filed 2016-04-29 |
| 2014-12-31 | $292.00M 10-K · filed 2017-03-01 | $291.60M 10-K · filed 2015-02-25 |
| 2013-12-31 | $115.30M 10-K · filed 2016-04-29 | $115.32M 10-K · filed 2014-02-28 |
| 2012-12-31 | $107.60M 10-K · filed 2015-02-25 | $107.64M 10-K · filed 2013-02-28 |
| 2011-12-31 | $58.52M 10-K · filed 2014-02-28 | |
| 2010-12-31 | $16.82M 10-K · filed 2013-02-28 | |
| 2009-12-31 | $7.42M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |